|View printer-friendly version|
Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences
- Citi’s 13th Annual
Biotech Conferenceon Thursday, September 6, 2018in Boston, MA.The Company will conduct one-on-one meetings with institutional investors at this conference.
Morgan Stanley16th Annual Global Healthcare Conference on Wednesday, September 12, 2018, at 2:15 p.m. Eastern Timein New York, NY. The Company will participate in a fireside chat presentation at the conference, which will be webcast live and available for replay from Portola's website at www.portola.com in the Investor Relations section.
Portola Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic diseases. The Company’s two FDA-approved medicines are Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], the first and only antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding, and Bevyxxa® (betrixaban), the first and only oral, once-daily Factor Xa inhibitor for the prevention of VTE in adult patients hospitalized for an acute medical illness. The company also is advancing cerdulatinib, a Syk/JAK inhibitor for the treatment of hematologic cancers.
|Investor Contact:||Media Contact:|
|Cara Miller||Laurie Masonson|
|Portola Pharmaceuticals||Pure Communications|